Nirogy therapeutics, originally named as “Nirogyone
Therapeutics”, is based in the biotech hub of Boston-Cambridge, MA.
Founded in 2014, launched in 2019 with seed funding, Nirogy was born as a
culmination of extensive search for new molecular targets in cellular
“Nirogy” means “without illness” in Sanskrit. Our
vision is to create a “curative path to end patient suffering afflicted
by many diseases”. Our mission is to discover and develop innovative
medicines for hard-to-treat chronic diseases such as cancer,
autoimmunity, and inflammation.
Dysregulated cellular metabolism
is increasingly recognized as the cause of many human diseases. The
recognition by the scientific community that in pathological conditions,
diverse cell types and their interactions, as opposed to single cell
types, participate in the genesis and progression of disease. This
concept has led us to explore the membrane-bound metabolic transporter
targets that are exposed to the extracellular microenvironment. These
transporter targets act as gatekeepers for intercellular communications
via transport of nutrients, metabolites, etc. Under pathological
conditions, these gatekeepers disrupt the homeostasis and dysregulate
the normal physiological functions.
We are developing a
transporter target platform that utilizes transporter biology,
structural biology, and computational chemistry to dissect underlying
mechanisms, guide drug design and development, and to inform patient
selection strategies for the development of novel medicines to address
today’s unmet medical needs.